Výsledky vyhledávání - "Donald Thornton"

Data from A Phase I Trial of Enzastaurin in Patients with Recurrent Gliomas

Autor: Howard A. Fine, Paul S. Albert, Donald Thornton, Luna Musib, Jennifer Walling, Svetlana Kotliarova, Paul Duic, Kraig Moore, Lyndon Kim, Teri N. Kreisl

Purpose: Enzastaurin is a selective inhibitor of protein kinase C β. Prior phase I studies did not show increased drug exposures with escalating once daily administration. Limits from gastrointestinal absorption may be overcome by twice daily dosing

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ba66e5356279b08adfdf4e1a9ed74d9
https://doi.org/10.1158/1078-0432.c.6516834.v1

Zobrazit plný text záznamu

Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy

Autor: Michael Andreeff, Zhihong Zeng, Sergej Konoplev, Hong Mu, Byung Sik Cho, Sheng Bin Peng, Marina Protopopova, Joseph R. Marszalek, Marina Konopleva, Zhiqiang Wang, Donald Thornton, Wencai Ma, Teresa McQueen, Jorge E. Cortes, R. Eric Davis

Publikováno v: Blood. 126:222-232

Targeting the stromal cell-derived factor 1α (SDF-1α)/C-X-C chemokine receptor type 4 (CXCR4) axis has been shown to be a promising therapeutic approach to overcome chemoresistance in acute myeloid leukemia (AML). We investigated the antileukemia e

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3529ab1a64cf899d9cf167c9a346cdb1
https://doi.org/10.1182/blood-2015-02-628677

Zobrazit plný text záznamu

Abstract OT1-03-04: A phase 2 study of abemaciclib in patients with brain metastases secondary to hormone receptor positive breast cancer

Autor: Donald Thornton, Carey K. Anders, Sara M. Tolaney, HT Wang, Suzanne Klise, C Zielinski

Publikováno v: Cancer Research. 76:OT1-03

Background: Abemaciclib, an oral drug administered twice daily on a continuous schedule, is an inhibitor of both CDK4 and CDK6. In study JPBA, abemaciclib demonstrated evidence of single-agent activity in a cohort of patients with heavily pretreated

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e572a289639f373b7163bac2102cded2
https://doi.org/10.1158/1538-7445.sabcs15-ot1-03-04

Zobrazit plný text záznamu

A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer

Autor: Young Suk Park, Jeanne Tie, Donald Thornton, Eyas Raddad, Yung-Jue Bang, Michael Michael, Sonya C. Tate, Tae Min Kim, Oday Hamid, Yoon-Koo Kang

Publikováno v: Targeted oncology. 12(4)

We report here a phase 1 study of LY2874455, a potent oral selective pan-fibroblast growth factor receptor (FGFR) inhibitor. The primary objective was to determine the recommended phase 2 dosing (RP2D). Secondary objectives included determining toxic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca4e7b1f0308333a7171ecac7b957ed0
https://pubmed.ncbi.nlm.nih.gov/28589492

Zobrazit plný text záznamu

A Phase I Trial of LY2510924, a CXCR4 Peptide Antagonist, in Patients with Advanced Cancer

Autor: John R. Stille, Eyas Raddad, John Polzer, Matthew D. Galsky, Stephanie Roberson, Paul Conkling, Nicholas J. Vogelzang, Mansoor N. Saleh, Donald Thornton

Publikováno v: Clinical Cancer Research. 20:3581-3588

Purpose: Overexpression of C-X-C motif receptor 4 (CXCR4) is implicated in tumor progression. LY2510924 is a peptide antagonist, which blocks stromal cell–derived factor-1 (SDF1) from CXCR4 binding. Experimental Design: This phase I study included

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e83d8c5e575a850e1b8dea9e4527a37b
https://doi.org/10.1158/1078-0432.ccr-13-2686

Zobrazit plný text záznamu

Phase I study of enzastaurin and bevacizumab in patients with advanced cancer: safety, efficacy and pharmacokinetics

Autor: Sabine Ermisch, Ting Wang, Michael A. Carducci, Jeannette Day, Deborah K. Armstrong, Lori Kornberg, Rodney Decker, Connie Collins, Steven J. Nicol, Donald Thornton, Lee P. Resta, Zhe Zhang, Nwabundo Nwankwo

Publikováno v: Investigational New Drugs

Summary Purpose Given distinct mechanism of actions of enzastaurin and bevacizumab, preclinical studies suggest enhanced antitumor activity in combination. This phase I study assessed the combination’s safety and efficacy. Patients and methods Six

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::472eebf5ca200034f61e7d9df3fcb0b9
https://doi.org/10.1007/s10637-012-9850-6

Zobrazit plný text záznamu

A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas

Autor: Paul S. Albert, John A. Butman, Howard A. Fine, Svetlana Kotliarova, Teri N. Kreisl, Lyndon Kim, Donald Thornton, Luna Musib

Publikováno v: Neuro-Oncology. 12:181-189

Enzastaurin, a potent inhibitor of protein kinase C-beta, inhibits angiogenesis and has direct cytotoxic activity against glioma cells in preclinical studies. Patients with recurrent high-grade gliomas were stratified by histology and use of enzyme-i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d75cf453ba156241865c63431ed9e03f
https://doi.org/10.1093/neuonc/nop042

Zobrazit plný text záznamu

Phase II Study of Enzastaurin, a Protein Kinase C Beta Inhibitor, in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Publikováno v: Journal of Clinical Oncology. 25:1741-1746

Purpose Protein kinase C beta (PKCβ) was identified by gene-expression profiling, preclinical evaluation, and independent immunohistochemical analysis as a rational therapeutic target in diffuse large B-cell lymphoma (DLBCL). We conducted a multicen

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1c7fc967c19dad992a2e06c2e528ffe
https://doi.org/10.1200/jco.2006.09.3146

Zobrazit plný text záznamu

A phase II study of abemaciclib as a monotherapy and in combination with other agents in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC)

Autor: Donald Thornton, Howard S. Hochster, Suzanne Klise, E. Gabriela Chiorean, Shivani Nanda

Publikováno v: Journal of Clinical Oncology. 35:TPS4150-TPS4150

TPS4150 Background: PDAC is a lethal tumor with unusual resistance to cytotoxic and targeted therapies, and pathogenesis frequently associated with hyperactive CDK 4&6 signaling. Pre-clinical models have demonstrated anti-proliferative activity with

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::73791d169ce7b0215a15a98508c78fc0
https://doi.org/10.1200/jco.2017.35.15_suppl.tps4150

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání